| Project/Area Number |
06671081
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Kanazawa University |
|---|
Principal Investigator |
SHIOBARA Shintaro Kanazawa University, Blood Transfusion Section, Associate prof., 医学部・附属病院, 助教授 (10135056)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
UEDA Mikio Kanazawa University, Internal Medicine (III), Assistant Prof., 医学部, 助手 (90193812)
NAKAO Shinji Kanazawa University, Internal Medicine (III), Assistant Prof., 医学部, 講師 (70217660)
|
|---|
| Project Period (FY) |
1994 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 1995: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1994: ¥700,000 (Direct Cost: ¥700,000)
|
|---|
| Keywords | Bone marrow transplantation / Graft-versus-leukemia effect / Graft-versus-host disease / Donor leukocyte transfusion / T cell clone / Adoptive immuno-therapy / Allo-cell therapy / 骨髄移植 / 抗白血病(GVL)効果 / 再発予防 |
|---|
| Research Abstract |
Graft-versus-leukemia (GVL) effect is important to maintain durable remission after allogeneic marrow transplantation. We have studied mixed hematopoietic chimerism in patients with CML received alloBMT and found a small number of host-derived normal hematopoietic progenitor cells may persist after lethal chemoradiotherapy despite Ph^1-positive clones could be eradicated ; suggesting patient T cells can recognize host-derived normal progenitor cells and Ph^1-positive clone separately.
Furthermore, we disclosed (1) ; donor leukocyte infusion (DLT) can enhance this GVL effect, (2) ; eradicate leukemia clone in transplant patients with relapsing CML,(3) ; this effect was depend on disease and stage at DLT.Preliminary survey of 26 Japanese patients with relapsing leukemia after alloBMT showed the induction rate of DLT were 100% of CML in chronic phase, 50% of MDS but 0% of CML in blastic phase and 20-30% of acute leukemia.
We have studied Tcell clonotype following DLT by using PCR product of T cell receptors and found one clear band in TCRV beta15+T cells ; suggested a specific T cell may eradicate leukemia without GVHD.
In summary, these data showed allo cell therapy like DLT opened a new promising area to eradicate leukemia clone.
|
